首页|PI3K/Akt信号通路调控子宫内膜异位症及中药干预作用研究进展

PI3K/Akt信号通路调控子宫内膜异位症及中药干预作用研究进展

扫码查看
子宫内膜异位症(endometriosis,EMs)是由于子宫内膜间质或者腺体异常定植到子宫腔被覆黏膜以外部位而导致的疾病。磷脂肌醇3激酶(phosphoinositide 3-kinase,PI3K)/蛋白激酶B(protein kinase B,Akt)信号通路参与病灶血管形成、异位组织细胞自噬与凋亡和迁移侵袭等过程,是调控EMs病理特性的经典通路之一。中药多组分、多靶点、多途径的特性在治疗EMs进程中优势显著,部分中药有效成分及中药复方通过干预PI3K/Akt信号通路,进而达到抑制内膜异位组织进展、减轻疼痛和缓解纤维化病变的治疗作用。该文通过阐述PI3K/Akt信号通路关键靶点与EMs的联系,归纳并总结国内外近年来中药通过调控PI3K/Akt信号通路治疗EMs的研究现状,旨在为利用中药及复方治疗EMs提供新的视角和思路。
Research progress on the regulation of endometriosis by PI3K/Akt signaling pathway and the intervention effect of traditional Chinese medicine
Endometriosis(Endometriosis,EMs)is a disease caused by abnormal colonization of the endometrial stroma or glands to sites other than the coated mucosa of the uterine cavity.Phospho-lipid inositol 3 kinase(phosphoinositide 3-kinase,PI3K)/protein kinase B(protein kinase B,Akt)sig-naling pathway is involved in the process of focal blood vessel formation,cell autophagic apoptosis,migration and invasion,and is one of the classic pathways regulating the pathological characteris-tics of EMs.The characteristics of multi-compo-nent,multi-target and multi-pathway of TCM have significant advantages in the treatment of EMs.Some TCM active components and TCM com-pounds can interfere with the PI3K/Akt signaling pathway,thus inhibiting the treatment of endome-triotic tissues,reducing pain and alleviating fibrotic lesions.By explaining the connection between the key targets of PI3K/Akt signaling pathway and EMs,this paper summarizes and summarizes the re-search status of EMs by regulating PI3K/Akt signal pathway in home and abroad,aiming to provide a new perspective and idea for the use of traditional Chinese medicine and compound to treat EMs.

endometriosisphosphoinositide 3-kinase/protein kinase B signaling pathwaytradi-tional Chinese medicineclassic formula

李泉洋、郝亚芳、吴国泰、王瑞琼

展开 >

甘肃中医药大学药学院,兰州 730000,甘肃

甘肃省中药药理与毒理学重点实验室,兰州 730000,甘肃

子宫内膜异位症 PI3K/Akt信号通路 中药 经典方剂

国家自然科学基金地区科学基金甘肃省青年博士基金甘肃省自然科学基金甘肃省优秀研究生"创新之星"项目

816606532021QB-07422JR5RA5882022CXZX-761

2024

中国临床药理学与治疗学
中国药理学会

中国临床药理学与治疗学

CSTPCD北大核心
影响因子:0.97
ISSN:1009-2501
年,卷(期):2024.29(5)
  • 82